Penumbra Inc. ( (PEN) ) has released its Q1 earnings. Here is a breakdown of the information Penumbra Inc. presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Penumbra, Inc. is a leading company in the medical technology sector, specializing in innovative thrombectomy solutions for various medical conditions, including ischemic stroke and venous thromboembolism, with a global reach in over 100 countries.
In its first-quarter earnings report for 2025, Penumbra, Inc. announced a significant increase in revenue and profitability, highlighting the company’s strong performance in the U.S. thrombectomy market and improvements in gross margins.
The company reported a 16.3% increase in total revenue, reaching $324.1 million, with U.S. thrombectomy revenue growing by 25%. Operating income saw a substantial rise to $40.4 million, and net income reached $39.2 million. The gross margin improved to 66.6%, driven by a favorable product mix and productivity gains. Despite a decrease in international revenue, the overall financial performance was bolstered by strong domestic sales.
Penumbra’s strategic focus on its thrombectomy products and operational efficiencies contributed to an adjusted EBITDA of $59.6 million, reflecting an 18.4% margin. The company also managed to reduce R&D expenses while increasing SG&A costs, maintaining a robust financial position with $376 million in cash and cash equivalents.
Looking ahead, Penumbra, Inc. maintains a positive outlook for 2025, with expectations of continued revenue growth in the U.S. thrombectomy franchise and further improvements in operating and gross margins, reflecting confidence in its strategic initiatives and market position.